Get the Stockscreener App
77.91
0.37%
0.29
After Hours:
78.04
0.13
+0.17%
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca PLC stock is traded at $77.91, with a volume of 3.29M.
It is up +0.37% in the last 24 hours and down -11.08% over the past month.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
See More
Previous Close:
$77.62
Open:
$78.09
24h Volume:
3.29M
Relative Volume:
0.77
Market Cap:
$241.16B
Revenue:
$49.13B
Net Income/Loss:
$6.44B
P/E Ratio:
39.35
EPS:
1.98
Net Cash Flow:
$6.97B
1W Performance:
+1.00%
1M Performance:
-11.08%
6M Performance:
+15.00%
1Y Performance:
+15.05%
1-Day Range:
$77.51
$78.10
1-Week Range:
$76.83
$78.78
52-Week Range:
$60.47
$87.67
Astrazeneca PLC Stock (AZN) Company Profile
Name
Astrazeneca PLC
Sector
Industry
Phone
44 20 3749 5000
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca PLC Stock (AZN) Latest News
AstraZeneca PLC ADR rises Monday, still underperforms market - MarketWatch
AstraZeneca (AZN): A Strong Buy as FDA Approves Key Cancer Treatments and Revenue Surges - Yahoo Finance UK
AstraZeneca outperforms market despite losses on the day - MarketWatch
Is AstraZeneca PLC (NASDAQ:AZN) The Top Global Stock To Buy Now? - Insider Monkey
Is AstraZeneca PLC (NASDAQ:AZN) The Top Global Stock To Buy Now? - Yahoo Finance
Questex’s Digital Pharma East Brought Pharma Marketing Professionals Together to Ignite Innovative Discussions and Marketing Strategies to Shape the Future of the Industry - GlobeNewswire Inc.
The AstraZeneca share price lifts 5% on a top-and-bottom earnings beat - MSN
Mackenzie Financial Corp Grows Holdings in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Is AstraZeneca PLC (AZN) the Best Cheap Growth Stock to Buy According to Analysts? - Insider Monkey
Is AstraZeneca PLC (AZN) the Best Cheap Growth Stock to Buy According to Analysts? - Yahoo Finance
AstraZeneca PLC (NASDAQ:AZN) is SAL Trading LLC’s 2nd Largest Position - Defense World
Oliver Lagore Vanvalin Investment Group Cuts Stock Position in AstraZeneca PLC (NASDAQ:AZN) - Defense World
UK's ex-PM Johnson says he planned raid on Dutch factory to get COVID vaccines - Marketscreener.com
Renaissance Technologies LLC Lowers Stock Position in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca PLC ADR falls Friday, underperforms market - MarketWatch
AstraZeneca PLC (NASDAQ:AZN) Short Interest Update - Defense World
AstraZeneca falls Friday, underperforms market - MarketWatch
The Zacks Analyst Blog Highlights Toyota Motor, AstraZeneca, Chubb, Air T and Preformed Line Products - Yahoo Finance
AstraZeneca Stock Up Almost 14% in 6 Months: Time to Buy? - MSN
Point72 Hong Kong Ltd Makes New Investment in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca’s Tagrisso gains FDA approval for stage III NSCLC - Pharmaceutical Technology
Sfmg LLC Has $220,000 Position in AstraZeneca PLC (NASDAQ:AZN) - Defense World
Top Stock Reports for Toyota, AstraZeneca & Chubb - Yahoo Finance
Fred Alger Management LLC Acquires 204,009 Shares of AstraZeneca PLC (NASDAQ:AZN) - Defense World
AstraZeneca Stock Up Almost 14% in 6 Months: Time to Buy? - Zacks Investment Research
AstraZeneca's Top-Selling Cancer Drug Tagrisso Receives FDA Green Light For Another Lung Cancer Indication - AOL
AstraZeneca rises Thursday, outperforms market - MarketWatch
AstraZeneca's Top-Selling Cancer Drug Tagrisso Receives FDA Green Light For Another Lung Cancer Indication - Yahoo Finance
AstraZeneca in AI collaboration with Immunai to inform cancer drug trials - Reuters
Global Bispecific Antibodies Clinical Trials Market Size FDA Approved Bispecific Antibodies Insight - Benzinga
AstraZeneca PLC (NASDAQ:AZN) Shares Sold by Marshall Wace LLP - MarketBeat
AstraZeneca PLC ADR outperforms market on strong trading day - MarketWatch
Gabelli Funds LLC Lowers Stake in AstraZeneca PLC (NASDAQ:AZN) - Defense World
AstraZeneca rises Wednesday, outperforms market - MarketWatch
Gabelli Funds LLC Lowers Stake in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Breast Cancer - AstraZeneca
AstraZeneca PLC (AZN): A Risky Bet on Emerging Cancer Treatments - Insider Monkey
AstraZeneca PLC (AZN): A Risky Bet on Emerging Cancer Treatments - Yahoo Finance
AstraZeneca PLC ADR falls Tuesday, underperforms market - MarketWatch
AstraZeneca falls Tuesday, underperforms market - MarketWatch
CHMP Endorses AstraZeneca's Fasenra in Rare Autoimmune Disease - Yahoo Finance
AstraZeneca: Buy This Big Pharma Stock At A Discount Now (NASDAQ:AZN) - Seeking Alpha
AstraZeneca PLC (NASDAQ:AZN) Shares Bought by Point72 DIFC Ltd - MarketBeat
EMA CHMP recommends AstraZeneca’s Fasenra to treat EGPA - Pharmaceutical Technology
Is AstraZeneca PLC (AZN) the Best Growth Stock To Buy According To George Soros? - Insider Monkey
Is AstraZeneca PLC (AZN) the Best Growth Stock To Buy According To George Soros? - Yahoo Finance
Breast Follows Lung In Another Survival Blow To AstraZeneca and Daiichi Sankyo’s Dato-DXd - Scrip
AstraZeneca falls Monday, underperforms market - MarketWatch
AstraZeneca Stock Falls After Disappointing Results in Breast Cancer Drug Trial - Yahoo Finance
AstraZeneca antibody drug conjugate fails to meet overall survival goal in breast cancer - Seeking Alpha
Here’s Why AstraZeneca PLC (AZN) Surged in Q2 - Insider Monkey
Astrazeneca PLC Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):